Tango Therapeutics, Inc. – NASDAQ:TNGX
Tango Therapeutics stock price today
$7.1
+3.97
+127.56%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 14 hours
Tango Therapeutics stock price monthly change
-68.67%
month
Tango Therapeutics stock price quarterly change
-68.67%
quarter
Tango Therapeutics stock price yearly change
-70.40%
year
Tango Therapeutics key metrics
Market Cap | 337.29M |
Enterprise value | 393.91M |
P/E | -3.76 |
EV/Sales | 10.82 |
EV/EBITDA | -2.53 |
Price/Sales | 11.34 |
Price/Book | 1.65 |
PEG ratio | -0.05 |
EPS | -1.13 |
Revenue | 37.23M |
EBITDA | -124.28M |
Income | -111.65M |
Revenue Q/Q | 12.22% |
Revenue Y/Y | 49.71% |
Profit margin | -434.86% |
Oper. margin | -444.23% |
Gross margin | 15.86% |
EBIT margin | -444.23% |
EBITDA margin | -333.81% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTango Therapeutics stock price history
Tango Therapeutics stock forecast
Tango Therapeutics financial statements
| Jun 2023 | 14.59M | -20.71M | -141.87% |
|---|---|---|---|
| Sep 2023 | 10.73M | -22.26M | -207.45% |
| Dec 2023 | 5.43M | -30.76M | -566.43% |
| Mar 2024 | 6.47M | -37.91M | -585.91% |
| Mar 2024 | 6.47M | -37.91M | -585.91% |
|---|---|---|---|
| Sep 2025 | 7.27M | -31.11M | -427.65% |
| Oct 2025 | 6.96M | -35.42M | -508.81% |
| Dec 2025 | 6.96M | -36.23M | -520.47% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 379328000 | 166.38M | 43.86% |
|---|---|---|---|
| Sep 2023 | 428189000 | 151.59M | 35.4% |
| Dec 2023 | 402567000 | 149.45M | 37.13% |
| Mar 2024 | 406222000 | 141.77M | 34.9% |
| Jun 2023 | -24.47M | 32.68M | 586K |
|---|---|---|---|
| Sep 2023 | -31.13M | -56.66M | 80.28M |
| Dec 2023 | -27.46M | 33.85M | 1.46M |
| Mar 2024 | -37.85M | -11.20M | 42.98M |
Tango Therapeutics alternative data
| Aug 2023 | 110 |
|---|---|
| Sep 2023 | 110 |
| Oct 2023 | 110 |
| Nov 2023 | 110 |
| Dec 2023 | 110 |
| Jan 2024 | 110 |
| Feb 2024 | 110 |
| Mar 2024 | 140 |
| Apr 2024 | 140 |
| May 2024 | 140 |
| Jun 2024 | 140 |
| Jul 2024 | 140 |
Tango Therapeutics other data
39.14%
-39.08%
of TNGX is owned by hedge funds
43
-39
34.37M
-34.37M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 186510 |
| May 2024 | 0 | 210000 |
| Jun 2024 | 0 | 174000 |
| Jul 2024 | 0 | 1880731 |
| Aug 2024 | 0 | 525000 |
| Sep 2024 | 0 | 142400 |
| Oct 2024 | 0 | 1508000 |
| Nov 2024 | 20000 | 5780000 |
Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs
Circling Bank On Tango Therapeutics
Tango Stock Surges On Peer Data Merits Excitement And Perspective
Tango Therapeutics: Partial Phase 1 Data Has Not Helped
Tango Therapeutics: Upcoming Proof Of Concept Data Is A Major Catalyst
Tango Therapeutics: Behind The Recent Momentum
-
What's the price of Tango Therapeutics stock today?
One share of Tango Therapeutics stock can currently be purchased for approximately $7.1.
-
When is Tango Therapeutics's next earnings date?
Unfortunately, Tango Therapeutics's (TNGX) next earnings date is currently unknown.
-
Does Tango Therapeutics pay dividends?
No, Tango Therapeutics does not pay dividends.
-
How much money does Tango Therapeutics make?
Tango Therapeutics has a market capitalization of 337.29M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 46.93% to 36.53M US dollars.
-
What is Tango Therapeutics's stock symbol?
Tango Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TNGX".
-
What is Tango Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Tango Therapeutics?
Shares of Tango Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Tango Therapeutics have?
As Jul 2024, Tango Therapeutics employs 140 workers.
-
When Tango Therapeutics went public?
Tango Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 3 Sep 2020.
-
What is Tango Therapeutics's official website?
The official website for Tango Therapeutics is tangotx.com.
-
Where are Tango Therapeutics's headquarters?
Tango Therapeutics is headquartered at 100 Binney Street, Cambridge, MA.
-
How can i contact Tango Therapeutics?
Tango Therapeutics's mailing address is 100 Binney Street, Cambridge, MA and company can be reached via phone at 857 320 4900.
Tango Therapeutics company profile:
Tango Therapeutics, Inc.
tangotx.comExchange:
NASDAQ
Full time employees:
140
Industry:
Biotechnology
Sector:
Healthcare
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
100 Binney Street
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001819133
ISIN: US87583X1090
CUSIP: 87583X109
